BASF Completes Acquisition of DOMO Chemicals' Shares in Alsachimie JV

BASF has acquired DOMO Chemicals' 49% stake in the Alsachimie joint venture and is now the sole owner of the production company for essential precursors of polyamide (PA) 6.6, including KA oil, adipic acid and hexamethylenediamine adipate (AH salt) in Chalampé, France. The parties have agreed not to disclose financial details of the transaction.

With the full acquisition of Alsachimie, BASF strengthens its operational presence at the Chalampé site - the European center for PA 6.6 production. The strategic decision enables BASF to optimize the backward integration of key raw materials and thus ensure a reliable and efficient supply along the PA 6.6 value chain. For DOMO Chemicals, the transaction is in line with its strategy to continue to focus on customized polyamide solutions for core segments such as the automotive, consumer goods, industrial goods and electrical and electronics industries.

The transaction complements a number of strategic measures taken by BASF to further strengthen PA 6.6 production at the Chalampé site, including the newly opened state-of-the-art hexamethylenediamine (HMD) plant and the expansion of PA 6.6 polymerization capacity at the nearby site in Freiburg, Germany.

Location in Chalampé, France
Location in Chalampé, France
© BASF

Company

Logo:

BASF SE

Avenue de Cortenbergh 60
1000 Bruxelles
Belgium

Company contact







Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.